89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
89Zr-TLX250-005
Phase 2 other terminated
Quick answer
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors for Cervical Cancer is a Phase 2 program (other) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Cervical Cancer
- Phase
- Phase 2
- Modality
- other
- Status
- terminated